Fig. 5: mTORC2 regulates PSGL-1/SELPLG via HIF2α/EPAS1. | Cancer Gene Therapy

Fig. 5: mTORC2 regulates PSGL-1/SELPLG via HIF2α/EPAS1.

From: Targeting mTORC2 in lung squamous cell carcinoma improves anti-tumor immunity through the PSGL-1-VISTA axis

Fig. 5

A Volcano plot showing differentially expressed genes from HCC2814 WT vs MLST8-KO cells (green = downregulated and red = upregulated). B Hallmark pathways presented for top 20 results based on fold enrichment, with an FDR cutoff of p < 0.05 performed using the ShinyGO 0.77 bioinformatic tool. C mRNA expression of the indicated genes was validated by real-time PCR. D Flow cytometric analysis of PSGL-1+ (% cells, FC) from KLN205-Ptennull WT and Mlst8-KO cells in vitro. Correlation between SELPLG and EPAS1 using the LUSC CPTAC (E) and LUAD CPTAC datasets (F) downloaded from cBioPortal. Linear regression lines of best fit and Pearson’s correlation analyses are shown. G 5 × 105 KLN205-Ptennull Mlst8-KO + EV or Mlst8-KO + HIF2α-CA cells were implanted in DBA/2 mice. Tumor growth was monitored, and tumor volume calculated (n = 23 mice per group). H mRNA expression of the indicated genes validated by real-time PCR in KLN205-Ptennull Mlst8-KO + EV or Mlst8-KO + HIF2α-CA cells. I Immunohistochemistry and quantification of PSGL-1 expression on KLN205-Ptennull Mlst8-KO + EV or Mlst8-KO + HIF2α-CA tumor samples (n = 4–5 mice per group). Scale bar: 20 μm. p values were determined by the mixed-effects model (REML) with Sidak multiple comparisons post hoc (G) and by two-tailed unpaired Student t test (C, D, H, I). *p < 0.05, **p < 0.01.

Back to article page